A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma
A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma
The CD20 antigen has become a major therapeutic target in the management of follicular and other Bcell non-Hodgkin’s lymphomas. The murine monoclonal antibody, tositumomab, on binding CD20, is able to induce antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and apoptosis. In addition, when radioiodinated, the antibody exploits the tumour’s sensitivity to ionising radiation by direct targeting of the malignant cell. Tositumomab and Iodine (I131) tositumomab (Bexxar®, GlaxoSmithKline, Philadelphia, PA, USA) is administered in two steps. The dosimetric step determines individual patient pharmacokinetics, allowing a patient- specific dose to be calculated. This is followed by the therapeutic step, with administration of the therapeutic dose between 7 and 14 days after the dosimetric dose. Over a decade’s worth of experience in clinical trials has determined the efficacy and safety of the regimen in a variety of clinical ci-rcumstances; establishment of exactly where the regimen fits amongst the algorithm for the management of follicular lymphoma continues.
577-588
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
April 2005
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Davies, A.J.
(2005)
A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma.
Expert Opinion on Biological Therapy, 5 (4), .
(doi:10.1517/14712598.5.4.577).
Abstract
The CD20 antigen has become a major therapeutic target in the management of follicular and other Bcell non-Hodgkin’s lymphomas. The murine monoclonal antibody, tositumomab, on binding CD20, is able to induce antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and apoptosis. In addition, when radioiodinated, the antibody exploits the tumour’s sensitivity to ionising radiation by direct targeting of the malignant cell. Tositumomab and Iodine (I131) tositumomab (Bexxar®, GlaxoSmithKline, Philadelphia, PA, USA) is administered in two steps. The dosimetric step determines individual patient pharmacokinetics, allowing a patient- specific dose to be calculated. This is followed by the therapeutic step, with administration of the therapeutic dose between 7 and 14 days after the dosimetric dose. Over a decade’s worth of experience in clinical trials has determined the efficacy and safety of the regimen in a variety of clinical ci-rcumstances; establishment of exactly where the regimen fits amongst the algorithm for the management of follicular lymphoma continues.
This record has no associated files available for download.
More information
Published date: April 2005
Identifiers
Local EPrints ID: 73335
URI: http://eprints.soton.ac.uk/id/eprint/73335
ISSN: 1471-2598
PURE UUID: d058be99-67a5-4208-aeec-7af91752a497
Catalogue record
Date deposited: 11 Mar 2010
Last modified: 14 Mar 2024 02:54
Export record
Altmetrics
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
